Abcam, ab223157, Anti-GIP antibody [EPR20410] - Low endotoxin, Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GIP antibody. Carrier free. Suitable for IHC-Fr, IHC-P, mIHC and reacts with Mouse, Rat, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20410,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:mIHC, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The antibody recognizes both full-length GIP and its active form.

Product details:
ab223157 is the carrier-free version of
ab209792
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.
What does low endotoxin mean?
Our low endotoxin, azide-free formats have low endotoxin level (1 EU/mg, determined by the TAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Glucose-dependent Insulinotropic Polypeptide (GIP) also known as gastric inhibitory polypeptide is a hormone with a molecular mass around 5 kDa. It is a 42-amino acid peptide secreted by the K cells in the duodenum and jejunum of the small intestine. This protein interacts with the GIP receptor which is found in various tissues including pancreatic beta cells adipose tissue and the central nervous system. Researchers utilize GIP ELISA for detecting and quantifying this peptide in research studies.
Biological function summary
The GIP plays a significant role in stimulating insulin secretion in response to glucose intake which does not function alone. It works as part of the enteroinsular axis influencing nutrient uptake and metabolism. GIP also regulates fat metabolism by acting on adipocytes therefore playing a part in energy homeostasis. The exploration of GIP activity often involves MSD assay development to better understand its biological implications.
Pathways
The glucose-stimulated insulin secretion pathway incorporates GIP to enhance the release of insulin from the pancreas. It interacts with other proteins such as insulin and glucagon-like peptide-1 (GLP-1) to exert its glucose-lowering effects. GIP's involvement in the incretin pathway supports the body's maintenance of energy balance and glucose homeostasis under normal physiological conditions.
Glucose homeostasis dysfunction links GIP to type 2 diabetes and obesity. Impairments in GIP secretion or receptor signaling are associated with these metabolic disorders. Studies suggest that dysregulation of GIP along with related proteins like insulin can contribute to disease progression. By targeting GIP researchers at places like Abcam are looking for potential therapies to tackle these health challenges.